中国同辐(01763.HK)附属与关连方组两间医药中心合营
中国同辐(01763.HK)公布关连交易,公司之非全资附属原子高科与新原实业订立贵阳合营协议,双方同意於中国成立贵阳合营公司;原子高科与新疆矿冶局亦订立新疆合营协议,双方同意於中国成立新疆合营公司。
根据贵阳合营协议,贵阳合营公司之注册资本应为3,250万元人民币(下同)。原子高科将以现金向贵阳合营公司注资2,762.5万元人民币,占股权85%。根据新疆合营协议之条款,新疆合营公司之注册资本应为3,200万元。原子高科将以现金向新疆合营公司注资2,432万元,占股权76%。
贵阳合营公司将作为贵州区域的医药中心,主要从事即时标记系列药物的生产和销售,正电子药物(18F-FDG)的生产和销售,其他放射性药品销售及相关技术谘询。新疆合营公司将作为新疆区域的医药中心,主要从事即时标记系列药物的生产和销售,正电子药物(18F-FDG)的生产和销售,其他放射性药品销售及相关技术谘询和服务。
中核集团通过其全资附属中国铀业持有新原实业100%的股权。新疆矿冶局则为中核集团通过其全资附属中国铀业直接控制和管理的事业单位。并构成公司关连交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.